tbuckley/cabot-search huggingface dataset:
Neuropilin-1 (Nrp-1) as a prognostic biomarker and potential drug target for pediatric medulloblastoma.
Authors: Lars Riedemann, Matija Snuderl, Ana Batista, Nathaniel David Kirkpatrick, Carmen Ruiz de Almodovar, Martin Hasselblatt, Claudia Rossig, Gabriel Dan Duda, Lei Xu, Dai Fukumura, Peter Carmeliet, Rakesh K. Jain
Journal: Journal of Clinical Oncology (2013)

2056 Background: Medulloblastoma survival rates have significantly improved over the last decades due to surgery and chemoradiation regimens. However, pediatric patients with high-risk disease and those with recurrence often succumb to their disease. The majority of children suffer from severe adverse effects of intense therapy regimens. We recently demonstrated the role of the Placental Growth Factor (PlGF)/Nrp-1 signaling pathway in medulloblastoma progression in preclinical models (Snuderl et al., Cell 2013). The aim of this study was to evaluate the role of Nrp-1 as a biomarker and therapeutic target in medulloblastoma patients. Methods: Thirty-two surgical samples of pediatric medulloblastoma were analyzed for expression of Nrp-1 and its ligand PlGF by immunohistochemistry, array-comparative genomic hybridization and deep gene sequencing. On an independent, clinically annotated cohort of 42 medulloblastoma samples, we evaluated the correlation between Nrp-1 expression and 5-year overall survival. The therapeutic relevance of Nrp-1 signaling was tested in a D283 orthotopic human xenograft mouse model using shRNA and a monoclonal antibody against Nrp-1. Results: Nrp-1 expression was detectable in 100% and PlGF in 90% of all medulloblastoma samples. No significant differences in expression could be detected between known histological or molecular medulloblastoma subtypes. Patients with high Nrp-1 expression had a significantly worse 5-year overall survival compared to patients with a low or moderate expression (40% vs. 86%, p = 0.0058). Treatment with an antibody against Nrp-1 or genetic silencing of Nrp-1 with shRNA significantly prolonged survival in a D283 orthotopic human xenograft mouse model (for both experiments: p &lt; 0.01). Conclusions: Nrp-1 is widely expressed across all molecular subgroups of medulloblastoma and its expression levels are inversely associated with survival of patients. Targeting Nrp-1 leads to a significant survival benefit in an orthotopic human xenograft mouse model. This data support the hypothesis that targeting the PlGF/Nrp-1 signaling pathway may be a novel therapy approach for pediatric medulloblastoma.
AB0916 Whipple disease: a rare disease difficult to diagnose
Authors: L Ferrieres, L Alric, M Laroche, D Bonnet, S Thebault
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Whipple disease is a very rare disease needing a long term treatment. The most frequent symptoms are recurrent arthralgia or arthritis, chronic diarrhoea, abdominal pain and weight loss. <h3>Objectives</h3> In this work, we have highlighted the main clinical features and diagnostic procedures that lead to the diagnosis and comment on the clinical response, treatment, and the factors of relapse. <h3>Methods</h3> Subjects were recruited from the Internal Medicine and Rheumatologic Departments of an University Hospital from November 1997 to January 2016. Overall, 12 subjects were finally diagnosed. <h3>Results</h3> Mean age was 54.3 years (age range: 30–81), with more male patients (58.3%). Almost all patients had articular symptoms and impaired general condition (91.7%); and a majority had digestive symptoms (75%). Regardless of the symptoms, the most efficient diagnostic tools were the PCR screening on the gastrointestinal biopsies and saliva (83.3% and 72.7% positive results, respectively). More than half of the patients relapsed (55.6%). The relapsing patients were older (63.2 (44–81)) and mostly male with a majority (60%) of digestive symptoms and a delayed diagnosis. <h3>Conclusions</h3> In current practice, it is highly difficult to diagnose Whipple disease. In order to decrease the delay between the first symptoms and the diagnosis, effective tools such as saliva and stools PCR should be used since higher delays of diagnosis lead to a higher number of relapses. <h3>Disclosure of Interest</h3> None declared
Annals Story Slam - Life and Times
Authors: Mena Gewarges
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 September 2017Annals Story Slam - Life and TimesFREEMena Gewarges, MDMena Gewarges, MDFrom University of Toronto, Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0053 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Life and Times "Life and Times," by Dr. Mena Gewarges (Duration 04:13)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Toronto, Toronto, Ontario, Canada.Current Author Address: Mena Gewarges, MD, University of Toronto, Toronto, Ontario, Canada; e-mail, mena.[email protected]utoronto.ca. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: SS1 ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
What Should I Do When I Hear the Call for Medical Assistance in a Plane?
Authors: Gregory L. Eastwood
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of colorectal cancer after a negative colonoscopy in low-to-moderate risk individuals: impact of a 10-year colonoscopy
Authors: Sanjay Murthy, Catherine Dubé, Alaa Rostom, Eric Benchimol, Robin Ducharme, Rinku Sutradhar, Linda Rabeneck, Lawrence Paszat, Jill Tinmouth
Journal: Endoscopy (2017)

Abstract Background and study aims National societies recommend colorectal cancer (CRC) screening 10 years after a normal (“negative”) colonoscopy in low-risk individuals. We studied the impact of a 10-year repeat colonoscopy on the risk of early incident CRC. Patients and methods We used health administrative data from Ontario, Canada, to conduct a population-based retrospective cohort study in 50 – 74-year-old individuals at low-to-moderate risk of CRC who had a negative colonoscopy between 1996 and 2001. We approximated exposure to repeat colonoscopy using an 8 – 12-year window. We excluded individuals who underwent lower endoscopy or colectomy, developed CRC, or were lost to follow-up between the baseline and repeat colonoscopies. We matched exposed individuals 1:1 to individuals who did not undergo lower endoscopy within 12 years for age, sex, and calendar year of baseline colonoscopy, and followed matched pairs for incident CRC. The primary analysis was multivariable hazards regression, adjusting for competing risks. Results A total of 13 350 matched pairs were observed for a median of 4.5 years (interquartile range 3.2 – 5.9 years). The cumulative probability of CRC following the matching date was 0.70 % (95 % confidence interval [CI] 0.42 % – 1.11 %) in individuals who underwent repeat colonoscopy and 0.77 % (95 %CI 0.48 % – 1.2 %) in individuals who did not undergo repeat colonoscopy. The adjusted hazard ratio for CRC was 0.91 (95 %CI 0.68 – 1.22). Conclusions We did not find an association between a second colonoscopy performed 10 years after a negative colonoscopy and early incident CRC. Our findings support the need for further studies on the utility of 10-year re-screening with colonoscopy in this setting.
AB0373 Analysis of risk factor for locomotive syndrome in patients with rheumatoid arthritis: data from chikara study
Authors: Y Yamada, M Tada, K Mandai, N Hidaka
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) are at a higher risk for sarcopenia due to joint destruction and chronic inflammation*1, which can lead to locomotive syndrome (LS), i.e., being restricted in the ability to walk or lead a normal life owing to a dysfunction in one or more of the parts of the musculoskeletal system*2. The prospective observational CHIKARA study (Correlation research of sarcopenia, skeletal muscle and disease activity in rheumatoid arthritis; registration number UMIN000023744) was begun in 2016 to investigate the correlation between RA disease activity and sarcopenia and LS. <h3>Objectives</h3> We investigated the relationship between LS and disease activity at baseline in patients with RA. <h3>Methods</h3> One hundred patients (78% women; average age, 66y) enrolled in the CHIKARA study were examined for body weight, muscle mass, fat mass, predicted bone mass, basal metabolic rate (BMR), leg muscle score, etc., using a body composition analyzer. Laboratory data, disease activity, Health Assessment Questionnaire (HAQ) and treatment were also investigated. LS was diagnosed using a questionnaire called Locomo-5. We investigated the correlation between LS and each status using univariate and multivariate analyses. <h3>Results</h3> Fifty-two percent of the patients with RA that we examined had LS. Mean disease duration was 5.5 years and mean DAS28-ESR was 3.55. Table 1 shows the risk factors for LS. Univariate analysis showed that age, percent body fat, body weight, visceral fat rating, leg muscles score, rheumatoid factor status and HAQ had significant associations to LS. Leg muscle score and HAQ were detected as significant factors by multivariate analysis. Patients whose leg muscle score was less than 90 had a significantly higher prevalence of LS by ROC curve analysis (Odds ratio 3.77, p=0.001). Disease activity and use of glucocorticoids or biological agents showed no significant relationship. <h3>Conclusions</h3> Lower leg muscle score and higher HAQ score are independent risk factors for LS among patients with RA. <h3>References</h3> Inui K., Koike T., Tada M., et al. Sarcopenia is apparent in patients with rheumatoid arthritis, especially those with biologics -TOMORROW study-. EULAR 2015 abstract (AB0359). Nakamura K., Ogata T. Locomotive Syndrome: Definition and Management. Clin Rev Bone Miner Metab. 2016; 14(2): 56–67. <h3>Disclosure of Interest</h3> None declared
Interventional Correction of Sinus Venosus Atrial Septal Defect and Partial Anomalous Pulmonary Venous Drainage
Authors: Mari Nieves Velasco Forte, Nick Byrne, Israel Valverde, Gorka Gomez Ciriza, Antony Hermuzi, Pimpak Prachasilchai, Gur Mainzer, Kuberan Pushparajah, Markus Henningsson, Tarique Hussain, Shakeel Qureshi, Eric Rosenthal
Journal: JACC. Cardiovascular imaging (2017)
AB1030 Identification of vertebral fractures in fracture liasion services across the united kingdom
Authors: J Sayer, S Stephenson
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Fracture Liaison Services (FLS) can prevent secondary fracture through systematic identification of low trauma fractures using dedicated case finding, with assessment and treatment of osteoporosis where necessary. Services are now being measured for quality against <i>Clinical Standards for Fracture Liaison Services</i> published by the National Osteoporosis Society in 2015.[1] The first standard asserts that all patients over 50 years with a newly reported vertebral fracture will be systematically and proactively identified. <h3>Objectives</h3> To evaluate provision for systematic identification of newly reported vertebral fractures in patients aged over 50 at Fracture Liaison Services (FLS) across the UK. <h3>Methods</h3> A gap analysis tool was used to measure service provision against standard one of the <i>Clinical Standards for Fracture Liaison Services</i>, relating to the systematic and proactive identification of vertebral fractures. Data was collected at 78 sites in the UK. <h3>Results</h3> 63% (49) of sites had <i>no</i> systematic process in place to identify vertebral fractures. Only 10% (8) sites identified <i>all</i> newly reported vertebral fractures. 27% (21) had procedures in place to identify <i>some</i> vertebral fractures, i.e. those within certain cohorts. There was considerable disparity across the UK. Sites in Scotland were significantly more likely to have comprehensive processes in place (38%, 6/16) than in the rest of the UK (3%, 2/62). <h3>Conclusions</h3> Systematic identification of vertebral fractures poses a particular challenge to services due to a number of factors. Vertebral fractures are difficult to identify as they tend not to present or be admitted in acute settings where FLS are primarily based. In addition, services require support from Radiology, including a commitment to avoid ambiguous terminology when reporting vertebral fractures. Furthermore, as a category, vertebral fractures fall between departments (Rheumatology, Orthopaedic, Fracture Clinic, A&amp;E, Spinal services) making systematic identification even more challenging. In the Fracture Liaison Service Database Facilities Audit (May 2016), the most frequently cited barrier to the identification of vertebral fractures was lack of a patient pathway.[2] Gap analysis shows a paucity of provision in the identification of vertebral fractures. This is the key driver for work underway in the NOS to develop a patient pathway for vertebral fractures, in conjunction with clinical experts, to promote best practice and best patient care. <h3>References</h3> https://www.nos.org.uk/health-professionals/fracture-liaison-services. https://www.rcplondon.ac.uk/projects/outputs/fls-db-facilities-audit-fls-breakpoint-opportunities-improving-patient-care. <h3>Disclosure of Interest</h3> None declared
An Average Face
Authors: Neelam A. Vashi, Mayra B. C. Maymone
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Season of Conception, Smoking, and Preeclampsia in Norway
Authors: Clarice R. Weinberg, Min Shi, Olga Basso, Lisa A. DeRoo, Quaker Harmon, Allen J. Wilcox, Rolv Skjærven
Journal: Environmental Health Perspectives (2017)

Preeclampsia (PE) is a dangerous and unpredictable pregnancy complication. A seasonal pattern of risk would suggest that there are potentially preventable environmental contributors, but prior analyses have not adjusted for confounding by PE risk factors that are associated with season of conception.Seasonal effects were modeled and tested by representing each day of the year as an angle on a unit circle and using trigonometric functions of those angles in predictive models, using "harmonic analysis." We applied harmonic Cox regression to model confounder-adjusted effects of the estimated day of the year of conception on risk of PE for births from the Medical Birth Registry of Norway for deliveries between 1999 and 2009. We also examined effect measure modification by parity, latitude (region), fetal sex, and smoking.In adjusted models, PE risk was related to season, with higher risk in spring conceptions and lower risk in autumn conceptions, with a risk amplitude (maximum compared with minimum) of about 20%. The pattern replicated across subpopulations defined by parity, latitude (region), fetal sex, and smoking.These results suggest that there is a seasonal driver for PE, with effects that are not modified by parity, latitude, fetal sex, or smoking. https://doi.org/10.1289/EHP963.
マイクロRNA応答性非ウイルスレポーターベクターを用いた生きている細胞分化中のマイクロRNA動力学のモニタリングと可視化【Powered by NICT】
Authors: Nakanishi Hideyuki, Miki Kenji, R Komatsu Kaoru, Umeda Masayuki, Mochizuki Megumi, Inagaki Azusa, Yoshida Yoshinori, Saito Hirohide
Journal: Biomaterials (2017)
Abstract 433: Mitochondrial Nadp-dependent Isocitrate Dehydrogenase is a Key Regulator in Vasomotor Function
Authors: Cuk-Seong Kim, Saet-byel Jung
Journal: Circulation Research (2016)

Mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDH2) plays an essential role protecting cells against oxidative stress-induced damage. A deficiency in IDH2 leads to mitochondrial dysfunction and the production of reactive oxygen species (ROS) in cardiomyocytes and cancer cells. However, the function of IDH2 in vascular endothelial cells is mostly unknown. In this study the effects of IDH2 deficiency on mitochondrial and vascular function were investigated in endothelial cells. IDH2 knockdown decreased the expression of mitochondrial oxidative phosphorylation (OXPHOS) complexes I, II and III, which lead to increased mitochondrial ROS (mtROS). In addition, the levels of fission and fusion proteins (Mfn-1, OPA-1, and Drp-1) were significantly altered and MnSOD expression also was decreased by IDH2 knockdown. Furthermore, knockdown of IDH2 decreased eNOS phosphorylation and nitric oxide (NO) concentration in endothelial cells. Interestingly, treatment with Mito-TEMPO, an mtROS-specific scavenger, blunted mitochondrial fission, fusion and mtROS production, and reduced the IDH2 knockdown-induced decrease in MnSOD expression, eNOS phosphorylation and NO production in endothelial cells. Endothelium-dependent vasorelaxation was impaired, and the concentration of bioavailable NO decreased in the aortic ring in IDH2 knockout mice. These findings suggest that IDH2 deficiency induces endothelial dysfunction through the induction of dynamic mitochondrial changes and impairment in vascular function.
FRI0279 Prevalence and factors associated with preconceptional counseling in women with autoimmune rheumatic diseases
Authors: G García-Garza, MA Saavedra, D Miranda-Hernández, A Sánchez, G García-Collinot, R Bustamante-González, LJ Jara
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Adequate prenatal counseling in women with autoimmune rheumatic diseases (ARDs) may help minimize maternal-fetal complications. However, the available information about the frequency and quality of prenatal counseling given to these patients is limited. <h3>Objectives</h3> To estimate the prevalence of preconceptional counseling and associated factors in women with ARDs. <h3>Methods</h3> A survey was conducted on socio-demographic data, gynecological-obstetric history, and domains related to preconception counseling in women with ARDs at the reproductive stage. It was defined as adequate preconception counseling if the patient knew that the pregnancy should be medically planned, that the complications are associated with severity/activity of the disease, that they should use an effective contraceptive method and that their medications may or may not be used during pregnancy. Descriptive statistics, Student9s T test for quantitative variables with normal distribution, Mann-Whitney U test for non-normal and chi-square distribution were used for categorical or ordinal variables. <h3>Results</h3> Of a total of 146 surveys, 131 were analyzed. Only 49 (37.4%) patients received adequate preconception counseling. Two thirds of the patients had systemic lupus erythematosus (Table). The time of evolution of the disease was a factor associated with receiving adequate counseling (5.6 vs 3.6 years, p=0.023). Illness, marital status, and level of education were not factors associated with adequate counseling. The adoption of a contraceptive method and the number of pregnancies were not different between the two groups. The history of use of embryotoxic/teratogenic drugs was associated with a higher frequency of adequate counseling (79.6% vs 41.5%, p=0.001). According to the patients, adequate counseling was given by the rheumatologist in 75.5% of the cases (p=0.001). <h3>Conclusions</h3> Adequate preconceptional counseling in our patients with ARDs at the reproductive stage is deficient. A multidisciplinary strategy is required to improve the frequency and quality of preconception counseling in patients with ARDs. <h3>Disclosure of Interest</h3> None declared